EXHIBIT 99

ONCOLOGIX TECH INC. ANNOUNCES SITE SELECTION AND INITIATION OF PRE-CLINICAL

(ANIMAL) TESTING OF THE ONCOSPHERE SYSTEM


GRAND RAPIDS, Mich.--(Marketwire) March 19, 2007 - Oncologix Tech Inc.'s (OTC
BB: OCLG.OB) wholly owned subsidiary Oncologix Corporation announced today that
the Institut de Cardiologie de Montreal (Montreal Heart Institute) and Dr. Raoul
Bonan have agreed to provide the facilities, equipment, and expertise necessary
to assist Oncologix in performing animal research studies with its Oncosphere
System. The studies are required to be completed as part of the data submitted
to the Food and Drug Administration (FDA) to support a request for initiation of
human clinical research.

One of Montreal Heart Institute's (MHI) primary missions is to develop and run
research and technology development programs related to their expertise in
vascular interventions. Given the reputation they have earned in basic and
clinical research, they often work with private businesses such as Oncologix. In
addition to their expertise in vascular interventions, Dr. Bonan and MHI have
teamed with industry in the development of interventional radiation based
treatments such as vascular brachytherapy and brachytherapy for atrial flutter
and fibrillation, which makes them a uniquely qualified location to conduct
animal studies with the Oncosphere System.

The first of two animal studies is scheduled to begin in March and both studies
should be completed by the end of 2007 for inclusion in an Investigational
Device Exemption (IDE) to the FDA requesting approval to begin human trials.
Accomplishing these goals continues to keep Oncologix on track with its plan to
initiate clinical trials with the Oncosphere System in early 2008 and to gain
commercial approval by the end of 2009.

According to Adam Lowe, President and COO of Oncologix, "We are extremely
pleased to working with Dr. Bonan and the Montreal Heart Institute. We have been
fortunate to align ourselves with individuals and organizations like these with
a long history of successful medical research and technology development."



In addition Stanley L. Schloz, Oncologix Tech Inc.'s Chief Executive Officer,
stated "The asset sale of the BestNet phone business to Interactive Media
Technologies, Inc was completed March 19, 2007. The company will now focus all
of it's energy and resources on it's medical subsidiary, Oncologix Corporation."




About Oncologix Tech Inc. and Oncologix Corp.:
----------------------------------------------

Oncologix Tech Inc., (formerly BestNet Communications Corp.) was formerly a
provider of long distance telephone communication services. On January 2007, the
Company entered into an agreement to dispose of the telephone business.

Oncologix Corporation, based in Atlanta GA, is a wholly owned subsidiary of
Oncologix Tech Inc. Oncologix is developing an advanced medical treatments for
soft tissue cancers; the Oncosphere System. The Oncosphere System is a
brachytherapy (radiation therapy) device being developed for the treatment of
soft tissue cancers. It is based on a radioactive micro-particle designed to
deliver therapeutic radiation directly to a tumor site by introducing the
micro-particles into the artery that feeds the tumor tissue.

This release contains forward-looking statements within the meaning of Section
21E of the Securities Exchange Act of 1934, as amended, which are intended to be
covered by the "safe harbor" created thereby. These statements include the plans
and objectives of management for future operations, including plans and
objectives. The forward-looking statements herein are based on current
expectations that involve judgments with respect to, among other things, future
economic, competitive and market conditions and future business decisions, all
of which are difficult or impossible to predict accurately and many of which are
beyond control of the company. Although the company believes that the
assumptions underlying the forward-looking statements are reasonable, any one of
the assumptions could be inaccurate and, therefore, can be no assurance that the
forward-looking statements included in this release will prove to be accurate.